Ajax Health Forms FlowMod to Develop System for Heart Failure Treatment

March 10, 2025—Ajax Health recently announced the formation of FlowMod, a new entity that intends to accelerate the creation, clinical validation, and regulatory approval for a system to treat heart failure.

Ajax Health, a KKR-backed medical device platform, stated that the new organization is the result of a collaboration between Boston Scientific Corporation, Ajax Health, and KKR using intellectual property developed by Boston Scientific.

According to Ajax Health, FlowMod will be led by Chief Executive Officer Philippe Marco, MD, the former President and Chief Operations Officer of Epix Therapeutics and CV Ingenuity, both Ajax-led companies that obtained premarket approval for cardiovascular devices.

“I am excited to work with the Ajax Health and KKR leadership teams again,” commented Dr. Marco in the press release. “We look forward to developing a meaningful advancement in the treatment of patients with heart failure, building upon the foundation established by Boston Scientific.”

As noted in the press release, Ajax Health is a turnkey growth solution for commercial-stage medtech companies. KKR is investing in FlowMod through its KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies.

In November 2024, Boston Scientific announced a definitive agreement to acquire Cortex, Inc., an Ajax Health company focused on the development of a diagnostic mapping solution in atrial fibrillation.

“On the heels of the Cortex transaction with Boston Scientific, we are thrilled to pursue this new path in interventional heart failure and the benefits it may bring to the millions of patients affected by this disease each year,” stated Duke Rohlen, Chief Executive Officer of Ajax Health. “Through this collaboration, we intend to bring a differentiated solution to physicians and their patients that we believe will make a positive impact on how heart failure is treated.”